@article {G{\'o}mez2020.11.02.20224659, author = {Juan G{\'o}mez and El{\'\i}as Cuesta-Llavona and Guillermo M. Albaiceta and Marta Garc{\'\i}a-Clemente and Carlos L{\'o}pez-Larrea and Laura Amado-Rodr{\'\i}guez and In{\'e}s L{\'o}pez-Alonso and Tamara Hermida and Ana I. Enr{\'I}quez and Helena Gil and Bel{\'e}n Alonso and Sara Iglesias and Beatriz Suarez-Alvarez and Victoria Alvarez and Eliecer Coto}, title = {The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster}, elocation-id = {2020.11.02.20224659}, year = {2020}, doi = {10.1101/2020.11.02.20224659}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {A polymorphism in the LZTFL1 gene located in the chemokine-receptor gene cluster (chromosome 3p) has been associated with the risk of developing COVID-19. The chemokine receptor-5 (CCR5) maps to this region, and the common 32 bp deletion variant (Δ32) has been associated with the extent of inflammatory disease and the outcome in several viral diseases. Several studies have also suggested that the pharmacological targeting of CCR5 could reduce the impact of SARS-CoV-2 infection and the severity of COVID-19. We sought to investigate whether this polymorphism was associated with the risk of moderate-severe COVID-19.We genotyped 294 patients who required hospitalization due to COVID-19 (85 were severe cases) and 460 controls. We found a significantly lower frequency of CCR5-Δ32 among the COVID-19 patients (0.10 vs 0.18 in controls; p=0.002, OR=0.48, 95\%CI=0.29-0.76). The difference was mainly due to the reduced frequency of CCR5-Δ32 carriers in the severe, significantly lower than in the non-severe patients (p=0.036). Of note, we did not find deletion-homozygotes among the patients compared to 1\% among controls. We also confirmed the association between a LZTFL1 variant and COVID-19. Our study points to CCR5 as a promising target for treatment of COVID-19, but requires validation in additional large cohorts. In confirmed by others, the genetic analysis of CCR5-variants (such as Δ32) might help to identify patients with a higher susceptibility to severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Spanish Plan Nacional de I+D+I Ministerio de Economia y Competitividad and the European FEDER, grant ISCIII-Red de Investigacion Renal-REDINREN RD16/9/5 (EC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee Research Principado AsturiasAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are available upon requesting to the corresponding author at: eliecer.coto@sespa.es}, URL = {https://www.medrxiv.org/content/early/2020/11/04/2020.11.02.20224659}, eprint = {https://www.medrxiv.org/content/early/2020/11/04/2020.11.02.20224659.full.pdf}, journal = {medRxiv} }